Cocrystal Pharma Inc. unveils investor presentation highlighting advances in broad-spectrum antiviral drug development
I'm PortAI, I can summarize articles.
Cocrystal Pharma Inc. has released an investor presentation detailing its progress in developing antiviral drugs for influenza, norovirus, and coronaviruses. The company uses a proprietary drug discovery platform based on Nobel Prize-winning technology. Key clinical assets, CDI-988 and CC-42344, have shown positive Phase 1 results. The company is also pursuing government contracts for pandemic preparedness and operates cost-efficiently with no debt. The full presentation is available online.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments